FDA Approval for KLYGEFA issued to ALEXION PHARM
The FDA approved Alexion Pharmaceuticals' Biologic License Application 761488 for KLYGEFA, a 600 MG solution for injection with the active ingredient gefurulimab, on 11/13/2026. The approval was for the original submission, and the marketing status is listed as prescription. The release does not say what condition the drug treats or how it performed in trials.
- Approval date
- 11/13/2026
- Strength
- 600 MG
- Application number
- 761488


